Anti-tumour effect of tocilizumab for osteosarcoma cell lines.
Anti-tumour effect of tocilizumab for osteosarcoma cell lines.
复制标题
DOI：
10.1302/2046-3758.911.bjr-2020-0123.r1
复制
发表时间：
2020-11
影响因子：
4.6
通讯作者：
Sudo A
中科院分区：
文献类型：
--
作者：
Hagi T;Nakamura T;Kita K;Iino T;Asanuma K;Sudo A
托珠单抗是一种白细胞介素-6（IL-6）受体（IL-6 R）靶向抗体，可增强癌症临床前模型中常规化疗的抗肿瘤作用。我们研究了托珠单抗在骨肉瘤（OS）细胞系中的抗肿瘤作用。我们使用143 B、HOS和Saos-2人OS细胞系。我们首先分别采用逆转录真实的时间定量聚合酶链反应（RT-qPCR）和蛋白质印迹法分析了OS细胞中IL-6基因表达和IL-6 R α蛋白表达。我们还使用增殖和侵袭测定来评估托珠单抗对OS细胞的作用。OS细胞系143 B、HOS和Saos-2表达IL-6 R。重组人IL-6处理增加了143 B和HOS细胞的增殖。托珠单抗处理降低了143 B、HOS和Saos-2的增殖和侵袭。总之，我们证实了OS细胞中IL-6的产生和IL-6 R的表达，并证明了托珠单抗抑制OS细胞的增殖和侵袭。引用这篇文章：骨关节研究2020;9（11）：821-826。
Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. We used the 143B, HOS, and Saos-2 human OS cell lines. We first analyzed the IL-6 gene expression and IL-6Rα protein expression in OS cells using reverse transcription real time quantitative-polymerase chain reaction (RT-qPCR) analysis and western blotting, respectively. We also assessed the effect of tocilizumab on OS cells using proliferation and invasion assay. The OS cell lines 143B, HOS, and Saos-2 expressed IL-6R. Recombinant human IL-6 treatment increased proliferation of 143B and HOS cells. Tocilizumab treatment decreased proliferation and invasion of 143B, HOS, and Saos-2. In conclusion, we confirmed the production of IL-6 and the expression of IL-6R in OS cells and demonstrated that tocilizumab inhibits proliferation and invasion in OS cells. Cite this article: Bone Joint Res 2020;9(11):821–826.